Kevin Joseph Fitzgerald sold $5.5M of ALNY
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC.. 12,128 shares at an average of $452.18, traded Nov 17, 2025, filed Nov 19, 2025.
Score components
- +15RoleOfficer
- +25Trade size$5.5M at market
- +10Share of holdings soldSold 36% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000123, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | MOption exercise Common Stock10b5-1 | +8,161 | $119.13 | $972k | 33,392 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -8,168 | $449.00 | $3.7M | 25,224 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -96 | $450.09 | $43k | 25,128 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -129 | $451.51 | $58k | 24,999 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -368 | $455.24 | $168k | 24,631 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -364 | $456.25 | $166k | 24,267 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -262 | $457.39 | $120k | 24,005 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -794 | $458.41 | $364k | 23,211 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -622 | $459.89 | $286k | 22,589 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -707 | $460.84 | $326k | 21,882 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -323 | $461.96 | $149k | 21,559 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -295 | $463.08 | $137k | 21,264 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -8,161 | $0.00 | $0 | 839 | Nov 19, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $12M 25,650 shares | -32% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $2.7M 5,959 shares | -23% | |
| 55Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 2,441 shares | -9% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $635k 1,405 shares | -5% | |
| 70Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $4.0M 8,924 shares | -12% | |
| 62Notable | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $1.7M 3,821 shares | -7% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8.4M 18,000 shares | -96% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $1.6M 3,474 shares | -12% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $5.1M 11,250 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.